Loading...
•
Sep 30, 2021
Allovir Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021 and shared progress on virus-specific T cell programs.
Key Takeaways
AlloVir reported a net loss of $45.5 million, or $0.72 per share, for the third quarter ended September 30, 2021. The company's research and development expenses were $33.1 million, and general and administrative expenses were $12.4 million. As of September 30, 2021, AlloVir had cash, cash equivalents, and marketable securities of $275.8 million.
Prioritizing prevention and treatment programs with the potential to transform transplant patient care and outcomes.
Positive interim data from posoleucel multi-virus prevention Phase 2 study will be presented at ASH.
Posoleucel Phase 3 study for the treatment of adenovirus and ALVR106 proof-of-concept clinical trial for the treatment of multiple respiratory viruses are on track to initiate this year.
AlloVir remains on track to initiate a Phase 3 study this year evaluating posoleucel for the treatment of adenovirus (AdV) in adult and pediatric allo-HSCT recipients.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...